SUNSHINE and SUNRISE Trials in HS

Author(s):

An expert in dermatology reviews the phase 3 SUNSHINE and SUNRISE trials evaluating the use of secukinumab given in 2-week intervals in patients with HS and shares clinical pearls for managing the condition.

EP: 1.Overview of Hidradenitis Suppurativa (HS): A Multifactorial Disease

EP: 2.Approaching Treatment and Addressing Unmet Needs for Mild-to-Moderate HS

EP: 3.Role of Immunomodulation in HS Treatment

EP: 4.Emerging Agents for the Management of HS

Now Viewing

SUNSHINE and SUNRISE Trials in HS

EP: 1.Overview of Hidradenitis Suppurativa (HS): A Multifactorial Disease

EP: 2.Approaching Treatment and Addressing Unmet Needs for Mild-to-Moderate HS

EP: 3.Role of Immunomodulation in HS Treatment

EP: 4.Emerging Agents for the Management of HS

EP: 5.SUNSHINE and SUNRISE Trials in HS

EP: 6.Overview and Diagnosis of Hidradenitis Suppurativa (HS)

EP: 7.Role of TNF-α Inhibitors in Moderate-to-Severe HS Treatment

EP: 8.Unmet Needs and Emerging Therapies in HS

EP: 9.Clinical Pearls for the Management of HS

EP: 10.Quality of Life for Patients With Hidradenitis Suppurativa (HS)

EP: 11.Diagnosis of HS

EP: 12.Treatment Options for HS

EP: 13.Emerging Therapy for Patients With HS

EP: 14.Clinical Pearls for Providers Treating HS